Mutanom chip technology
Gene mutations are permanent changes in individual gene segments. Such changes can either occur only in the tumor (somatic mutations, not hereditary) or in all of the body’s cells (germline mutations, hereditary). Mutations play a key part in a tumor’s genesis and its further development. In precision medicine, they are of vital importance. They can either be the target of new drugs or, by analyzing the changes they yield in metabolic pathways and signal cascades, indicate a specific, indirect therapeutic procedure. When considering the significance of mutations for the tumor development and its treatment, it is necessary to differentiate between driver mutations and subordinate passenger mutations. The mutational pattern in tumor diseases varies greatly from person to person. Since more and more, mutations are the target of new cancer drugs, it is imperative to know the respective tumor disease’s individual mutational status. With next-generation sequencing, a quantum leap in the technology of mutational analysis has been made. This is the basis for analyzing a number of mutations simultaneously. The degree of parallel analysis ranges from 16 cancer and tumor suppressor genes to all of the human body’s more than 20.000 genes. Depending on the clinical issue, a 16-gene-assay may suffice (for instance as a basic examination in colon cancer or non small cell lung carcinoma). If however a peptide (artificially produced protein fragments) cancer vaccine is planned, a mutational analysis of all of the more than 20.000 genes becomes necessary (mutanome analysis). We are happy to consult you in determining which of the different MultiOncogenMutationTests (MOMs) is best suited to your individual case.
Cryopreserved tumor tissue is ideal for the high resolution mutanome chip technology. Formalin-fixed paraffin-embedded tissue can be used for all other MOMs. Minuscule tissue samples (for instances, a few of slices skin from a punch biopsy or tissue collected in fine-needle aspiration biopsies) suffice. Detailed information can be found in our Specimen Collection and Transport Kits.
Duration of Testing
Except for mutanome analysis (4-6 weeks), all MOMs are carried out within a maximum of 14 days.
In all of Germany, the lead time for transporting cryopreserved tissue or tissue from pleural effusions and ascitic fluid is 24 hours before a planned procedure. We will contact the respective pathological institute to arrange for the FFPE tissue blocks. A single call will do, just ring us at 0211 4477 4388 (landline) or 0171 784 989 4 (cell). We will take care of the entire logistic process for you.